Notícias

In this month’s Mailbag, Fools write in about market caps, parenting, AI, adding to winning investments, and what can happen when decades of patient investing quietly compound into opportunities to help others.

Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Brown Advisory, an investment management company, released its “Brown Large-Cap Growth Strategy” for the first-quarter 2026 investor letter. A copy of the letter is available to download here. The Brown Advisory Large-Cap Growth Strategy experienced a decline in the first quarter of 2026, modestly trailing the Russell 1000 Growth Index. Despite negative absolute returns amidst volatility, […]

Intuitive Surgical, Inc. (NASDAQ:ISRG) has declined more than 29% over the past 6 months and is now trading close to its 52-week lows. The downward pressure stems from regulatory scrutiny regarding instrument reuse and concerns over Chinese competition. ​However, the Street expects the stock to rebound, with analysts’ 12-month average price target suggesting more than […]

Abbott's broad healthcare reach and Intuitive's robotic surgery focus present distinct financial strengths and risks for investors weighing portfolio strategy.

Stryker (NYSE:SYK) and Intuitive Surgical (NASDAQ:ISRG) both closed the books on Q1 2026 with sharply different results. Stryker absorbed a March 11 cyberattack and heavy restructuring charges while defending its joint replacement franchise. Intuitive posted another crisp beat on the back of da Vinci 5 adoption. Two medtech giants, two very different quarters. A Cyber ... Stryker Vs. Intuitive Surgical: Stryker’s Joint-Replacement Moat Over Intuitive’s Premium Valuation

The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A select few continue to execute at a high level, growing their market dominance and delivering strong returns.

The company dominates the robotic surgery market.

Intuitive Surgical's Quintuple Aim strategy is driving premium pricing as da Vinci 5 adoption grows, with innovation-led revenue growth outpacing procedure growth.

Intuitive Surgical has been a huge winner over the long term, but there's a potential opening for new investors right now.

In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $404.27, denoting a +1.14% move from the preceding trading day.

Intuitive Surgical, Inc. (NASDAQ:ISRG) ranks among the best set-it-and-forget-it stocks to buy right now. On June 2, Piper Sandler restated its Overweight rating and $580 target on Intuitive Surgical, Inc. (NASDAQ:ISRG). The firm’s recent field check with the head of robotics at a prominent U.S. healthcare institution confirmed the firm’s positive opinion of the company. […]

Goldman Sachs and several industry analysts have publicly backed Intuitive Surgical's core business, following concerns about new rules on instrument reuse. The commentary argues that regulatory driven changes to reuse policies are unlikely to cause major disruption to Intuitive Surgical's revenue model. The defense comes after a period of share price pressure and renewed debate about the long term outlook for NasdaqGS:ISRG. Intuitive Surgical enters this debate with its stock under...

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.

These companies' innovative qualities could help them get ahead of their peers in capitalizing on AI.

Intuitive Surgical Inc. (NASDAQ:ISRG) is one of the 10 best robotics and automation stocks to invest in. On June 17, Good Samaritan Hospital highlighted its use of Intuitive Surgical’s da Vinci Single Port robotic platform, which enables surgeons to perform complex procedures through a single small incision. Dr. Mohammed Al-Temimi explained that the system allows […]

Peggy Johnson, a former Microsoft and Magic Leap executive who is now the CEO of Agility Robotics, used a CNBC segment to announce that her company is going public through a SPAC merger with Churchill Capital Corp., a deal she describes as the first pure-play humanoid robotics company to tap public markets. The company, a ... Humanoid Robotics CEO: The First Pure-Play Robot Company Is About to Go Public

ISRG stands out over ZBH as stronger revenue growth, rising procedure demand, and expanding AI-driven innovation support better upside in 2026.

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the top high-conviction stocks to buy according to hedge funds. Deutsche Bank cut the price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $366 from $440 on June 2 while maintaining a Sell rating on the shares. The stock also received a rating update from BofA on May 12, […]

Intuitive Surgical (ISRG) has been one of the year’s most punished large-cap healthcare names. The maker of the da Vinci surgical robot has watched its stock fall about 28% in 2026, even as revenue keeps climbing. Analysts have piled on. Deutsche Bank slashed its target. Bank of America trimmed its ...

While the market fixates on a disruptive quarter for Stryker stock, the company's powerful ability to convert profit into hard cash reveals a deeper, under-appreciated resilience.

Intuitive Surgical, Inc. (NASDAQ:ISRG) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down. Inquiring about the stock, a caller asked if it is a buy. Cramer replied: Too much competition, too much competition… Used to be king, […]

ISRG raises its 2026 outlook after strong Q1 results, but can broad-based procedure growth offset emerging headwinds in key U.S. and global markets?

Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Grow Funds, an investment Advisor, released its Q1 2026 investor letter for “GROW Small Cap Equity Long/Short Fund”. A copy of the letter can be downloaded here. In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outperforming the Russell 2000 Growth Index’s –2.80%, HFRI Equity Hedge Index’s -0.24%, and the HFRI Fundamental […]

With a short percentage of shares outstanding of 2.05%, Intuitive Surgical, Inc. (NASDAQ:ISRG) is among the 7 Best Longevity and Anti-Aging Stocks to Buy. On June 2, Deutsche Bank reduced its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $366 from $440 while maintaining a Sell rating on the shares. The revised target reflects the firm’s updated valuation outlook for the […]

In late May, Intuitive Surgical announced leadership changes effective July 1, promoting nearly 20-year company veteran Taylor Patton to Chief Commercial and Marketing Officer while moving current CCMO Henry Charlton into a new Senior Vice President of Global Business Operations role focused on global value generation. These executive moves come as Intuitive manages FDA safety alerts, product recalls, and rising competition, all while relying on its large installed da Vinci base and...

If you are wondering whether Intuitive Surgical stock is starting to offer better value or still pricing in a lot of optimism, you are not alone. The share price closed at US$406.78, with returns declining 2.3% over the past week, 7.1% over the past month, and 27.6% year to date. The return over the past 1 year is down 21.0% and the 3 and 5 year returns are 25.1% and 33.7% respectively. Recent coverage has focused on how Intuitive Surgical sits within medical technology and minimally...

Intuitive Surgical (ISRG) is back in focus after recent trading data showed the stock down about 7% over the past month and around 14% over the past 3 months, sharpening attention on its long term track record. See our latest analysis for Intuitive Surgical. At a share price of $406.78, Intuitive Surgical’s recent 1 month share price return of about 7% down and year to date share price return of about 28% down point to fading short term momentum, even though the 3 year total shareholder...

Artificial intelligence is changing the world, but this healthcare technology is quietly doing the same.